BioSpace Collaborative

Academic/Biomedical Research
News & Jobs
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  C2C Services & Suppliers™
Europe
Asia

DIVERSITY

PROFILES
Company Profiles

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Research Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
Get Our Industry eNewsletter FREE email:    
   

Lophius Biosciences GmbH Achieves First Clinical Proof of Principle for T-Track® TB for Detection of Active Tuberculosis and Receives Research Funding


11/8/2012 2:19:34 PM

Regensburg, Germany, November 8, 2012 / B3C newswire / - Lophius Biosciences, a leader in the field of novel T cell based diagnostic test systems, reported today about its first successfully concluded clinical Proof of Principle study with respect to detection of active tuberculosis (TB) using its novel T-Track® TB test which is based on Lophius Biosciences proprietary Reverse T Cell Technology (RT Technology).

The clinical Proof of Principle was concluded in India with a cohort of 44 patients. Results demonstrate that the T-Track® TB test was able to detect active TB in in 10 of 12 non-treated patients. Besides its high sensitivity and specificity the T-Track® TB test also demonstrated a remarkably short turnaround time of 2 days which compares favorably to currently used classical detection methods. In summary, these results imply that the T-Track® TB test could represent an innovative and fast detection approach for this area of strong medical need.

For further test development Lophius Biosciences has been awarded research funding of 140K EUR under the scope of the ZIM-solo-program from the German government. This funding should help to broaden the scope of the T-Track® TB tests with respect to detection of latent TB and potential patient-monitoring of treated TB subjects. The company will present first results at Medica mid November 2012 in Düsseldorf.

"We are very pleased to have accomplished clinical Proof of Principle for our second proprietary technology platform. Our short-term goal is geared towards test optimization and further validation in a bigger patient cohort" said Dr. Michael Lutz, CEO of Lophius Biosciences.

About Lophius Biosciences

Lophius Biosciences GmbH develops and markets innovative T cell based testing systems for diagnostics and possible therapy control in the fields of transplantation, infection and autoimmune diseases.

Contact

Lophius Biosciences GmbH

Josef-Engert-Str. 13

D-93053 Regensburg

Phone: +49 941 6309 1972

Email: info@lophius.de

www.lophius.de


Read at BioSpace.com


   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES
 

//-->